43Z Stock Overview
Develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Schrödinger, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.00 |
| 52 Week High | US$33.75 |
| 52 Week Low | US$15.56 |
| Beta | 1.5 |
| 11 Month Change | -13.56% |
| 3 Month Change | -13.37% |
| 1 Year Change | -39.60% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 43Z | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -7.9% | -2.2% | -1.9% |
| 1Y | -39.6% | 19.1% | 12.3% |
Return vs Industry: 43Z underperformed the German Healthcare Services industry which returned 19.9% over the past year.
Return vs Market: 43Z underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| 43Z volatility | |
|---|---|
| 43Z Average Weekly Movement | 8.5% |
| Healthcare Services Industry Average Movement | 5.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 43Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 43Z's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 867 | Ramy Farid | www.schrodinger.com |
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Schrödinger, Inc. Fundamentals Summary
| 43Z fundamental statistics | |
|---|---|
| Market cap | €1.16b |
| Earnings (TTM) | -€183.55m |
| Revenue (TTM) | €182.79m |
6.4x
P/S Ratio-6.3x
P/E RatioIs 43Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 43Z income statement (TTM) | |
|---|---|
| Revenue | US$200.63m |
| Cost of Revenue | US$69.21m |
| Gross Profit | US$131.41m |
| Other Expenses | US$332.88m |
| Earnings | -US$201.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.77 |
| Gross Margin | 65.50% |
| Net Profit Margin | -100.42% |
| Debt/Equity Ratio | 0% |
How did 43Z perform over the long term?
See historical performance and comparison